摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methyl-1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)pyrimido[5,4-c]quinoline-2,4(1H,3H)-dione | 1222999-88-3

中文名称
——
中文别名
——
英文名称
3-methyl-1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)pyrimido[5,4-c]quinoline-2,4(1H,3H)-dione
英文别名
3-methyl-1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylpyrimido[5,4-c]quinoline-2,4-dione
3-methyl-1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)pyrimido[5,4-c]quinoline-2,4(1H,3H)-dione化学式
CAS
1222999-88-3
化学式
C35H29F3N6O3
mdl
——
分子量
638.649
InChiKey
WZIOHGSMWQVWIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    47
  • 可旋转键数:
    4
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    90
  • 氢给体数:
    0
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
    摘要:
    The mTOR It protein is a master regulator of cell growth and proliferation, and inhibitors of its kinase activity have the potential to become new class of anticancer drugs. Starting from quinoline I, which was identified in a biochemical mTOR assay, we developed a tricyclic benzonaphthyridinone inhibitor 37 (Torin 1), which inhibited phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin I exhibits 1000-fold selectivity for mTOR over P13K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. Torin was efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrated good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and per tissues. These results demonstrate that Torin I is a useful probe of mTOR-dependent phenomena and that benzo-naphthridinones represent a promising scaffold for the further development of mTOR-specific inhibitors with the potential for clinical utility.
    DOI:
    10.1021/jm101144f
点击查看最新优质反应信息

文献信息

  • SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF
    申请人:Gray Nathanael
    公开号:US20110288091A1
    公开(公告)日:2011-11-24
    The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.
    本发明涉及mTORC1和mTORC2的小分子调节剂,其合成和中间体。这些小分子调节剂在治疗增生性疾病(例如良性肿瘤、癌症、炎症性疾病、自身免疫性疾病、糖尿病性视网膜病变)和代谢性疾病方面有用。提供了新的小分子,其抑制mTORC1、mTORC2和PI3K相关蛋白质中的一个或多个。讨论了提供可溶性mTORC1和mTORC2复合物的新方法,以及使用可溶性复合物以高通量方式筛选抑制性化合物的方法。
  • Soluble mTOR complexes and modulators thereof
    申请人:Gray Nathanael
    公开号:US08394818B2
    公开(公告)日:2013-03-12
    The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.
    本发明涉及mTORC1和mTORC2的小分子调节剂、其合成以及中间体。这样的小分子调节剂在治疗增生性疾病(如良性肿瘤、癌症、炎症性疾病、自身免疫疾病、糖尿病性视网膜病变)和代谢性疾病方面非常有用。提供了新的小分子,它们抑制mTORC1、mTORC2和PI3K相关蛋白中的一个或多个。讨论了提供可溶性mTORC1和mTORC2复合物的新方法,以及使用可溶性复合物进行高通量筛选抑制剂的方法。
  • [EN] SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF<br/>[FR] COMPLEXES MTOR SOLUBLES ET MODULATEURS ASSOCIÉS
    申请人:WHITEHEAD BIOMEDICAL INST
    公开号:WO2010044885A3
    公开(公告)日:2010-09-02
  • Modulators of MTOR Complexes
    申请人:Whitehead Institute For Biomedical Research
    公开号:EP2350053B1
    公开(公告)日:2013-12-11
  • INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS
    申请人:Moorman Nathaniel
    公开号:US20120190676A1
    公开(公告)日:2012-07-26
    The present invention provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response.
查看更多